Safety and Feasibility of Adipose Derived Regenerative Cells (ADRCs) in the Treatment of Deep Partial Thickness and Full Thickness Thermal Wounds (RELIEF)

Trial Profile

Safety and Feasibility of Adipose Derived Regenerative Cells (ADRCs) in the Treatment of Deep Partial Thickness and Full Thickness Thermal Wounds (RELIEF)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2018

At a glance

  • Drugs ECCS 50 (Primary)
  • Indications Burns
  • Focus Adverse reactions
  • Acronyms RELIEF
  • Sponsors Cytori Therapeutics
  • Most Recent Events

    • 09 Nov 2017 According to a Cytori Therapeutics media release, status changed from planning to recruiting.
    • 10 Aug 2017 According to a Cytori Therapeutics media release, enrollment in this trial is expected to begin in Q4 2017.
    • 10 Apr 2017 According to a Cytori Therapeutics media release, the company has that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for a pilot clinical trial to evaluate Cytori Cell Therapy in patients with thermal burn injury.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top